| Rethinking ovarian cancer: recommendations for improving outcomes S Vaughan, JI Coward, RC Bast, A Berchuck, JS Berek, JD Brenton, ... Nature Reviews Cancer 11 (10), 719-725, 2011 | 1155 | 2011 |
| Whole–genome characterization of chemoresistant ovarian cancer AM Patch, EL Christie, D Etemadmoghadam, DW Garsed, J George, ... Nature 521 (7553), 489-494, 2015 | 949 | 2015 |
| Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer DD Bowtell, S Böhm, AA Ahmed, PJ Aspuria, RC Bast, V Beral, JS Berek, ... Nature reviews Cancer 15 (11), 668-679, 2015 | 654 | 2015 |
| Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens FM Behan, F Iorio, G Picco, E Gonçalves, CM Beaver, G Migliardi, ... Nature 568 (7753), 511-516, 2019 | 319 | 2019 |
| OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer GC Sellar, KP Watt, GJ Rabiasz, EA Stronach, L Li, EP Miller, CE Massie, ... Nature genetics 34 (3), 337-343, 2003 | 223 | 2003 |
| HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer EA Stronach, A Alfraidi, N Rama, C Datler, JB Studd, R Agarwal, ... Cancer research 71 (13), 4412-4422, 2011 | 153 | 2011 |
| DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance EA Stronach, M Chen, EN Maginn, R Agarwal, GB Mills, H Wasan, ... Neoplasia 13 (11), 1069-IN35, 2011 | 127 | 2011 |
| Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer DS Matassa, MR Amoroso, H Lu, R Avolio, D Arzeni, C Procaccini, ... Cell Death & Differentiation 23 (9), 1542-1554, 2016 | 96 | 2016 |
| Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival W Dai, JM Teodoridis, C Zeller, J Graham, J Hersey, JM Flanagan, ... Clinical Cancer Research 17 (12), 4052-4062, 2011 | 86 | 2011 |
| Microarray coupled to quantitative RT–PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells S Ngan, EA Stronach, A Photiou, J Waxman, S Ali, L Buluwela Oncogene 28 (19), 2051-2063, 2009 | 83 | 2009 |
| Comparing the characteristics of gene expression profiles derived by univariate and multivariate classification methods M Zucknick, S Richardson, EA Stronach Statistical applications in genetics and molecular biology 7 (1), Article7, 2008 | 76 | 2008 |
| Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells N Chapman-Rothe, E Curry, C Zeller, D Liber, E Stronach, H Gabra, ... Oncogene 32 (38), 4586-4592, 2013 | 72 | 2013 |
| BARX2 induces cadherin 6 expression and is a functional suppressor of ovarian cancer progression GC Sellar, L Li, KP Watt, BD Nelkin, GJ Rabiasz, EA Stronach, EP Miller, ... Cancer research 61 (19), 6977-6981, 2001 | 58 | 2001 |
| MicroRNAs associated with small bowel neuroendocrine tumours and their metastases HC Miller, AE Frampton, A Malczewska, S Ottaviani, EA Stronach, R Flora, ... Endocr Relat Cancer 23 (9), 711-726, 2016 | 49 | 2016 |
| Novel PCR-based diagnostic tools for Charcot-Marie-Tooth type 1A and hereditary neuropathy with liability to pressure palsies. EA Stronach, C Clark, C Bell, A Löfgren, NG McKay, V Timmerman, ... Journal of the peripheral nervous system: JPNS 4 (2), 117-122, 1999 | 48 | 1999 |
| Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression EA Stronach, GC Sellar, C Blenkiron, GJ Rabiasz, KJ Taylor, EP Miller, ... Cancer research 63 (24), 8648-8655, 2003 | 43 | 2003 |
| The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma EA Stronach, P Cunnea, C Turner, T Guney, R Aiyappa, S Jeyapalan, ... Oncotarget 6 (31), 31593, 2015 | 40 | 2015 |
| Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting F Iorio, FM Behan, E Gonçalves, SG Bhosle, E Chen, R Shepherd, ... BMC genomics 19 (1), 1-16, 2018 | 39 | 2018 |
| Biomarker assessment of HR deficiency, tumor BRCA1/2 mutations, and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapy EA Stronach, J Paul, KM Timms, E Hughes, K Brown, C Neff, M Perry, ... Molecular Cancer Research 16 (7), 1103-1111, 2018 | 35 | 2018 |
| Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening G Picco, ED Chen, LG Alonso, FM Behan, E Gonçalves, G Bignell, ... Nature communications 10 (1), 1-12, 2019 | 32 | 2019 |
